Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of Extreme Hypofractionation Including Pelvic Nodes for High Risk Prostate Cancer Using MgRT (MRI Guided Radiation Therapy)

NCT05676463 is registered in ClinicalTrials.gov with Thomas Jefferson University as lead sponsor.

NCT NCT05676463
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05676463 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of Extreme Hypofractionation Including Pelvic Nodes for High Risk Prostate Cancer Using MgRT (MRI Guided Radiation Therapy)
Lead sponsor
Thomas Jefferson University
Phase
Phase 2
Overall status
Terminated
Start date
November 16, 2022
Completion date
October 24, 2025
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate adenocarcinoma, stage iiib prostate cancer ajcc v8, stage iiic prostate cancer ajcc v8